BioMérieux Receives CE Mark for Biomarker Assay for Mild TBI
BioMérieux, which signed an agreement in 2017 with Banyan Biomarkers to commercialize its TBI assay, has obtained the CE Mark for its assay to detect two biomarkers associated with mild traumatic brain injury (mTBI).
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies
Capsida Biotherapeutics Inc. and UF startup Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs.
Atsena Therapeutics Doses First Patient in Phase I/II Clinical Trial of ATSN-201 for Treatment of X-Linked Retinoschisis
Atsena Therapeutics announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
National Cade Prize for Innovation Names 21 Finalists
Judges for 2023’s National Cade Prize for Innovation named this year’s 21 Fibonacci Finalists. Finalists will compete to win $10,000 in their respective category group—Agriculture and Environmental, Healthcare/Biomedical, IT/Tech, Energy, and Wildcard. One of the five category winners will be selected as the Inventivity™ Grand Prize winner and take home an additional $50,000 prize. Two UF startups -- Lactovid and Analyz -- are listed among the Fibonacci Finalists.
Atsena Therapeutics Receives FDA Clearance of an Investigational Gene Therapy for X-Linked Retinoschisis
The U.S. Food and Drug Administration (FDA) has cleared Atsena Therapeutics' Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
College of Medicine Opens Clinical Research Hub
To further support clinical research faculty, the UF College of Medicine Office of Research recently launched the Clinical Research Hub, which will provide enterprisewide leadership, create standards and policies and establish a shared infrastructure for clinical research in the college. The new hub aims to facilitate increased collaboration, simplify clinical research processes, develop pathways for researchers and advance overall research excellence.
UF to Lead National Trial Testing Nerve Block to Alleviate Headache from Subarachnoid Hemorrhage
A multidisciplinary team of neurocritical care, neurosurgery and pain medicine investigators from the University of Florida has been awarded a $12.9 million National Institutes of Health grant to test a novel way to relieve pain from sudden, excruciating headaches stemming from a burst brain aneurysm that causes bleeding.
Celebrating a Mentor – College Honors Faculty Members With New Award Named for the Late Mavis Agbandje-McKenna, PhD
Mavis Agbandje-McKenna, PhD, a UF College of Medicine professor in the department of biochemistry and molecular biology and the director of the Center for Structural Biology, dedicated 32 years to advancing discoveries in adeno-associated viruses, or AAV, and other parvoviruses at UF before passing away in 2021. In addition to being a globally recognized parvovirus researcher, she demonstrated an unwavering commitment to training the next generation of scientists.
UF Health research sheds new light on nicotine and morning brew
In a cell-based study, UF researchers identified two compounds in coffee that directly affect certain high-sensitivity nicotine receptors in the brain. In smokers, these brain receptors can be hypersensitive after a night of nicotine withdrawal.
UF researchers discover new way to inhibit virus that causes COVID-19
When the virus that causes COVID-19 enters the body, it hijacks cellular proteins and suppresses the human inflammatory response, allowing the virus to spread. University of Florida researchers have discovered a novel way in the lab to fight rapidly evolving strains of coronaviruses by breaking that cycle.
